Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer

[1]  G. Tiram,et al.  Amphiphilic poly(α)glutamate polymeric micelles for systemic administration of siRNA to tumors. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[2]  Adva Krivitsky,et al.  Systemic delivery of siRNA by aminated poly(&agr;)glutamate for the treatment of solid tumors , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[3]  K. Kataoka,et al.  Recent progress in development of siRNA delivery vehicles for cancer therapy. , 2016, Advanced drug delivery reviews.

[4]  Adva Krivitsky,et al.  Structure-Function Correlation of Aminated Poly(α)glutamate as siRNA Nanocarriers. , 2016, Biomacromolecules.

[5]  V. Ellenrieder,et al.  MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies , 2016, Oncogene.

[6]  D. Santini,et al.  State of the art biological therapies in pancreatic cancer. , 2016, World journal of gastrointestinal oncology.

[7]  A. Dreher.  Modeling Survival Data Extending The Cox Model , 2016 .

[8]  Mark E. Davis,et al.  Clinical experiences with systemically administered siRNA-based therapeutics in cancer , 2015, Nature Reviews Drug Discovery.

[9]  J. Boxerman,et al.  Paclitaxel Poliglumex, Temozolomide, and Radiation for Newly Diagnosed High-grade Glioma: A Brown University Oncology Group Study , 2014, American journal of clinical oncology.

[10]  Robert Langer,et al.  Small RNA combination therapy for lung cancer , 2014, Proceedings of the National Academy of Sciences.

[11]  T. Śledziński,et al.  Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. , 2014, World journal of gastroenterology.

[12]  S. Batra,et al.  Novel Pancreatic Cancer Cell Lines Derived from Genetically Engineered Mouse Models of Spontaneous Pancreatic Adenocarcinoma: Applications in Diagnosis and Therapy , 2013, PloS one.

[13]  R. Spizzo,et al.  Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. , 2013, Cancer discovery.

[14]  C. Dang.  MYC, metabolism, cell growth, and tumorigenesis. , 2013, Cold Spring Harbor perspectives in medicine.

[15]  Qiang Yu,et al.  PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. , 2013, Cancer discovery.

[16]  T. Hazbun,et al.  Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer , 2012, Molecular Cancer Therapeutics.

[17]  A. Bader.  miR-34 – a microRNA replacement therapy is headed to the clinic , 2012, Front. Gene..

[18]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[19]  J. Burnett,et al.  RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.

[20]  Wei Wu,et al.  MicroRNA-Based Therapeutics for Cancer , 2012, BioDrugs.

[21]  Jennifer P Morton,et al.  MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma , 2011, Clinical Cancer Research.

[22]  Hannah J. Whiteman,et al.  AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. , 2011, Cancer research.

[23]  C. Tung,et al.  Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models , 2011, Gut.

[24]  A. Meining,et al.  In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging , 2011, Proceedings of the National Academy of Sciences.

[25]  Joshua T. Mendell,et al.  Restitution of Tumor Suppressor MicroRNAs Using a Systemic Nanovector Inhibits Pancreatic Cancer Growth in Mice , 2011, Molecular Cancer Therapeutics.

[26]  V. Galic,et al.  Paclitaxel poliglumex for ovarian cancer , 2011, Expert opinion on investigational drugs.

[27]  M. Hashizume,et al.  MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer , 2011, Annals of Surgical Oncology.

[28]  D. Brown,et al.  The promise of microRNA replacement therapy. , 2010, Cancer research.

[29]  B. Liu,et al.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  Y. Pilpel,et al.  p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC , 2010, Cell Death and Differentiation.

[31]  A. Jimeno,et al.  A Fine-Needle Aspirate–Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.

[32]  Min Zhang,et al.  MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells , 2009, PloS one.

[33]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[34]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[35]  P. Ofek,et al.  Targeting Angiogenesis-Dependent Calcified Neoplasms Using Combined Polymer Therapeutics , 2009, PloS one.

[36]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[37]  Carola Berking,et al.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer , 2008, Cell cycle.

[38]  M. Socinski,et al.  Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  A. Judge,et al.  Overcoming the innate immune response to small interfering RNA. , 2008, Human gene therapy.

[40]  Georges von Degenfeld,et al.  Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. , 2007, Nature chemical biology.

[41]  Michael A. Beer,et al.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.

[42]  J. Yates,et al.  Large-Scale Identification of c-MYC-Associated Proteins Using a Combined TAP/MudPIT Approach , 2007, Cell cycle.

[43]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[44]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[45]  David A. Tuveson,et al.  The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics , 2006, Clinical Cancer Research.

[46]  O. Boerman,et al.  INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES , 2006, Drug Metabolism and Disposition.

[47]  A. Ullrich,et al.  Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.

[48]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[49]  Kinneret Keren,et al.  Dynamic imaging of protease activity with fluorescently quenched activity-based probes , 2005, Nature chemical biology.

[50]  W. Weichert,et al.  Overexpression of Polo-Like Kinase 1 Is a Common and Early Event in Pancreatic Cancer , 2005, Pancreatology.

[51]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[52]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[53]  M. Tsao,et al.  Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. , 2004, Molecular cancer therapeutics.

[54]  Jianjun Cheng,et al.  Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles , 2004, Cancer biology & therapy.

[55]  R. Larsson,et al.  Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients , 1998, European Journal of Clinical Pharmacology.

[56]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[57]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.